I-Corps: In-vitro tool that provides multiparametric information in real-time to determine the efficacy and toxicity of a new drug

I-Corps：实时提供多参数信息以确定新药功效和毒性的体外工具

• 批准号: 2130085
• 负责人: Kimberly Stroka
• 金额: $ 5万
• 依托单位: University of Maryland, College Park
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2130085&HistoricalAwards=false
• 关键词: Corps; vitro; tool; provides; multiparametric

The broader impact/commercial potential of this I-Corps project is in improving the development of more effective drug treatments (e.g., therapeutics or regenerative medicine approaches) for diseases such as cancer, heart disease, and stroke. This device provides the necessary information to determine, at an early stage in the drug development, if the new product will provide sufficient gain or benefit. It is expected that this technology will simplify data processing while providing a high quality, cost-effective, and time-efficient approach. This approach will free material resources and personnel that can be devoted to the development of new products. The advantages of this new system will reduce the time for new products to reach the marketplace while helping to provide higher efficacy treatments for cancer and other diseases with less toxic side effects.This I-Corps project will provide a new in vitro tool with the capability of gathering information on multiple parameters to determine the efficacy and toxicity of new drugs. This technology provides the means for collecting data on cell responses to (bio)chemical and physical stimuli continuously and in real-time. Contrary to many conventional detection methods that rely on collecting data at the end of the experiment (endpoint), this system collects data continuously, providing a dynamic account of cell responses with a reduced number of samples. This technology will also leverage continuous access to cell behavior data to enable the development of a data analytics approach for impedance spectroscopy-type measurements. The development of this research tool into a more automated system will broaden its impact and acceptance not only in the biopharmaceutical industry but also in academic and biomedical environments and the biotechnology industry.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个I-Corps项目的更广泛的影响/商业潜力是改善更有效的药物治疗的开发（例如，治疗学或再生医学方法）用于诸如癌症、心脏病和中风的疾病。该器械提供了必要的信息，以在药物开发的早期阶段确定新产品是否将提供足够的收益或获益。 预计该技术将简化数据处理，同时提供高质量、高成本效益和高时间效率的方法。这种方法将释放物质资源和人员，可以专门用于开发新产品。这一新系统的优势将缩短新产品上市的时间，同时有助于为癌症和其他疾病提供更高疗效的治疗方法，同时减少毒副作用。I-Corps项目将提供一种新的体外工具，能够收集多个参数的信息，以确定新药的疗效和毒性。该技术提供了连续和实时收集细胞对（生物）化学和物理刺激反应的数据的方法。与许多依赖于在实验结束时（终点）收集数据的传统检测方法相反，该系统连续收集数据，以减少的样品数量提供细胞响应的动态账户。该技术还将利用对细胞行为数据的持续访问，以开发用于阻抗谱类型测量的数据分析方法。将这一研究工具发展成一个更加自动化的系统将不仅在生物制药行业，而且在学术和生物医学环境以及生物技术行业扩大其影响和接受度。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。